Soleus Capital Management »

Vyne Therapeutics shares owned by Soleus Capital Management

Quarter-by-quarter ownership of Vyne Therapeutics (VYNE) shares owned by Soleus Capital Management from 13F filings

Historical chart of Soleus Capital Management investment in Vyne Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Vyne Therapeutics held by Soleus Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Vyne Therapeutics by Soleus Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $1.6M 704k 2.33

More positions owned by Soleus Capital Management

Teva Pharmaceutical Inds Sponsored Ads (TEVA)
United Therapeutics Corporation (UTHR)
GSK Sponsored Adr (GSK)
Rayzebio
Edap Tms S A Sponsored Adr (EDAP)
Organogenesis Hldgs (ORGO)
Humana (HUM)
Celcuity (CELC)
Iradimed (IRMD)
Essa Pharma Com New (EPIX)
SurModics (SRDX)
Hca Holdings (HCA)
Vaxcyte (PCVX)
Neuropace (NPCE)
Nuvalent Inc-a (NUVL)

View all positions for Soleus Capital Management

Top funds holding Vyne Therapeutics

Cormorant Asset Management
Eventide Asset Management
Citadel Advisors
Soleus Capital Management
DSC Advisors
Palo Alto Investors
AlphaCentric Advisors
Exome Asset Management
Fred Alger Management
Vanguard Group
Millennium Management
Hrt Financial
Us Bancorp
Bank of America Corporation
Royal Bank of Canada

View all funds holding Vyne Therapeutics